WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST After 2020 set records for private biotechs’ ability to raise cash, 2021 shattered them once again—by a whopping 26%, for a total of $28.5 billion changing hands. But while the figures can be eye-watering, they become less rosy as you dig deeper. Despite some gargantuan fundraisings, the number of rounds and the number of dollars raised decreased each quarter after starting the year with a bang. Our list of biotech’s top 10 money raisers, plus the top stories of this week, follow below. | |
|
Featured Story | By Nick Paul Taylor Bristol Myers Squibb and Nektar have read the last rites to their huge, failed cancer collaboration. With two more late-stage trials failing, the partners have ended clinical development of a combination they once saw as the future of immuno-oncology. read more |
| |
|---|
|
| | Webinar: How to break down silos and think like a learning health ecosystem Tuesday, April 26, 2022 | 3pm ET / 12pm PT Healthcare inefficiencies are compromising the patient experience. With the industry facing increased digitization, pressure from consumers to adapt to wearable technology, and regulatory changes calling for greater price transparency, it needs to adapt. We will discuss how technology can bring stakeholders together to find solutions that will benefit everyone. Register Now. |
Top Stories Of The Week By Kevin Dunleavy In its Oncology Deep Dive presentation last week, Gilead said it plans to derive a third of its revenue from oncology products by 2030. That will require a major transformation as the company made less than $2 billion of its $27 billion in sales from cancer products in 2021. read more By Max Bayer 2021 marked the second consecutive year of record-breaking private financing for biotechs, with more than $28 billion raised. The total haul is a 26% increase from 2020, and the stunning dollar amounts came even as the public market depreciated throughout the year. Here's our look at the 10 biotechs that raked in the largest VC investments. read more By Fraiser Kansteiner After a winding path to a coronavirus vaccine launch that still hasn’t reached the U.S., Novavax's program could be destined to reap billions of dollars in sales this year, one group of analysts predicts. read more By Max Bayer TG Therapeutics is winding down its oncology program after removing the FDA-approved cancer med Ukoniq from the market in two indications that were granted accelerated approval in addition to withdrawing an approval request for a combo med dubbed U2. read more By Zoey Becker Despite high expectations, Pfizer's COVID-19 antiviral Paxlovid has encountered relatively low demand worldwide lately, Reuters reports. Pfizer is expecting more than $20 billion in sales from the treatment this year. read more By Max Bayer Novavax touted early data of its combo vaccine for the flu and COVID-19, saying the shot elicited an immune response comparable to standalone flu and COVID shots. The results come as the company is still awaiting a decision from the FDA on its EUA submission for its COVID jab. read more By Andrea Park There seems to be no limit to Philips’ ventilator safety woes. Nearly a full year after initiating a recall of 5.2 million respiratory devices, the company continues to accumulate safety notices for those and other devices in its vast respiratory portfolio. read more By Ben Adams Healthcare professionals want high quality, low quantity and good structure when it comes to email campaigns. If they fail to get this balance right, pharma marketers risk entrenching so-called “digital fatigue” from doctors as the world comes out of the pandemic. read more By Angus Liu Gilead Sciences’ Kite Pharma has further beefed up its cell therapy manufacturing footprint as a recent FDA approval for Yescarta promises to increase demand. read more By Gabrielle Masson Researchers at UCLA have unveiled a novel road map tracking blood stem cell development in the human embryo, findings that could help develop new treatments for blood cancers and inherited blood disorders. read more Resources Sponsored By: H1 More than 570 clinical trials in Ukraine have been disrupted. Unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. What role do rescue sites play? Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Blue Matter, strategic consultants in the life sciences What’s in store for the oncology market in 2022 and beyond? This paper looks at 5 trends driving the market. Sponsored by: Thermo Fisher Scientific Learn how to position quality as a central component within your raw material sourcing strategies for the chemicals used throughout your workflows. Download the free whitepaper from Thermo Fisher Scientific. Accelerating Immuno-Oncology and Oncology Drug Development Using Humanized Mice Thursday, April 21, 2022 | 12pm ET / 9am PT Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Forum May 24, 2022 | Free Virtual Event Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Free Virtual Event Fierce Health Payer Summit October 12, 2022 | Free Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Free Virtual Event Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA | 